<DOC>
	<DOCNO>NCT00547443</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving sorafenib together high-dose chemotherapy external-beam radiation therapy may kill tumor cell . PURPOSE : This randomized phase I/II trial study side effect best dose sorafenib give together high-dose carboplatin , paclitaxel , external-beam radiation therapy treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Sorafenib High-Dose Carboplatin , Paclitaxel , External-Beam Radiation Therapy Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine median survival randomization patient receive carboplatin paclitaxel high-dose radiation therapy ( HDRT ) regimen sorafenib tosylate . Secondary - To determine overall response rate , failure-free survival , survival patient receive carboplatin/paclitaxel 74 Gy HDRT regimen sorafenib tosylate . - To determine feasibility concurrent sorafenib tosylate chemoradiation measure safety ( rate grade 3 high radiation relate esophagitis pulmonary toxicity chemotherapy relate grade 4 hematological non-hematological toxicity occur within 60 day start treatment ) compliance ( completion treatment regimen minor variation ) . - To correlate outcome ( survival , toxicity , quality life ) biological parameter . OUTLINE : This multicenter study . - Phase I : - Chemoradiotherapy : Patients receive paclitaxel IV 60 minute carboplatin IV 30 minute day 1 . Treatment repeat weekly 7 week . Patients undergo concurrent high-dose external beam radiotherapy ( HDRT ) 5 day week 7.5 week . Cohorts patient also receive escalate dos oral sorafenib tosylate twice daily 7 week . - Consolidation therapy : Beginning week 11 , patient receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 . Treatment repeat every 3 week 6 week . Patients also receive oral sorafenib tosylate maximum tolerate dose ( MTD ) twice daily . - Maintenance : Patients receive oral sorafenib tosylate twice daily MTD . - Phase II : Patients randomize 1 2 treatment arm . - Arm I : - Chemoradiotherapy : Patients receive paclitaxel , carboplatin , HDRT phase I . - Consolidation therapy : Patients receive paclitaxel carboplatin phase I . - Arm II : - Chemoradiotherapy : Patients receive paclitaxel , carboplatin , HDRT phase I . Patients also receive oral sorafenib tosylate phase I MTD . - Consolidation therapy : Patients receive paclitaxel , carboplatin , sorafenib tosylate MTD phase I . - Maintenance : Patients receive sorafenib tosylate MTD phase I . After completion study therapy , patient follow every 3 month 2 year every 6 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically cytologically document nonsmall cell lung cancer ( NSCLC ) Any follow subtypes allow : Adenocarcinoma ( include bronchoalveolar cell ) Squamous cell carcinoma Large cell anaplastic carcinoma ( include giant clear cell carcinoma ) Poorly differentiate ( otherwise specify ) NSCLC No metastasis ( patient must M0 ) Stage IIIA ( T1 T2 N2 T3N12 ) stage IIIB ( T4 N T N2 N3 ) disease Measurable disease Tumors adjacent vertebral body allow long gross disease encompass radiation boost field The boost volume must limit &lt; 50 % ipsilateral lung volume Pleural effusion transudate , cytologically negative , nonbloody allow radiation oncologist feel tumor still encompass within reasonable field radiotherapy Pleural effusion see chest CT small tap allow Exclusion criterion : Totally resect tumor Exudative , bloody , cytologically malignant effusion Known brain metastasis Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis PATIENT CHARACTERISTICS : Inclusion criterion : Zubrod performance status 01 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL ( prior transfusion ) Total bilirubin ≤ 1.5 mg/dL AST ALT ≤ 3 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Glucose ≤ 2 time ULN Creatinine ≤ 2.0 mg/dL FEV_1 ≥ 1,200 mL Weight loss ≤ 10 % past 3 month Not pregnant nursing Negative pregnancy test Women childbearing potential male participant unwilling unable use acceptable method contraception throughout study 4 week completion treatment use prohibit contraceptive method INR &lt; 1.5 PT/PTT within normal limit Exclusion criterion : Known allergy murine protein Cremophor EL Active pulmonary infection responsive conventional antibiotic History severe chronic obstructive pulmonary disease require ≥ 3 hospitalization past year Cardiac disease include follow : Congestive heart failure &gt; class II NYHA Unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) Myocardial infarction within past 6 month Cardiac ventricular arrhythmia require antiarrhythmic therapy Patients neuropathy &gt; grade 1 Evidence malignancy past 2 year except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ cancer Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal medical management Known HIV infection chronic hepatitis B Active clinically serious infection &gt; CTCAE grade 2 Thrombolic embolic event , cerebrovascular accident include transient ischemic attack , within past 6 month Pulmonary hemorrhage bleed event ≥ CTCAE grade 2 within past 4 week Any hemorrhage bleeding event ≥ CTCAE Grade 3 within past 4 week Serious nonhealing wound , ulcer , bone fracture Evidence history bleed diathesis coagulopathy Known suspect allergy sorafenib tosylate agent give course trial Any condition impair patient 's ability swallow whole pill Any malabsorption problem Significant traumatic injury within past 4 week PRIOR CONCURRENT THERAPY : Inclusion criterion : Recovered exploratory thoracotomy Concurrent anticoagulation treatment agent warfarin heparin allow provide INR PT/PTT requirement meet Exclusion criterion : Prior systemic chemotherapy lung cancer and/or thoracic/neck radiotherapy reason Prior surgical resection present cancer Prior therapy moleculartargeted drug ( lung cancer ) Currently participate phase III therapeutic clinical trial and/or participate phase III therapeutic clinical trial previous 30 day Major surgery open biopsy within past 4 week Concurrent Hypericum perforatum ( St. John 's wort ) rifampin ( rifampicin ) Other concurrent anticancer drug , include hormonal , immunotherapeutic , chemotherapeutic agent Steroids acute symptom management , adrenal failure , septic shock , antiemetic allow Hormones administer nondiseaserelated condition ( e.g. , insulin diabetes ) allow Amifostine concurrently radiotherapy within 3 month completion radiotherapy Concurrent colonystimulating factor ( i.e. , filgrastim [ GCSF ] sargramostim [ GMCSF ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
</DOC>